TL;DR: A dual-wavelength red and violet laser device used at home twice daily for 3 weeks reduced foot pain by 30% or more in 73% of people with painful diabetic neuropathy, compared to 32% with sham treatment.
Painful diabetic peripheral neuropathy (DPN) affects millions of people with diabetes and often resists standard medication. This randomized controlled trial tested whether a home-use laser device could provide relief when added to existing pain management routines.
Researchers enrolled 64 adults with painful DPN across four U.S. clinical sites. Participants were randomly assigned to use either an active device emitting simultaneous 640 nm red and 405 nm violet laser light, or an identical-looking sham device. Both groups treated their feet for 5 minutes per foot, twice daily, for 3 weeks. Critically, all participants continued taking their regular pain and neuropathy medications unchanged, so the laser therapy was positioned as an add-on treatment rather than a replacement.
The primary endpoint asked a binary question: did participants achieve at least a 30% reduction in foot pain by week 3? The gap was substantial. In the active treatment group, 72.7% of participants met this threshold compared to 32.3% in the sham group, a difference of 40.5 percentage points (95% CI 18.1 to 62.9, p = 0.0024). Average pain scores on a 0-100 scale dropped 33.4 points with active treatment versus 20.0 points with sham, a statistically significant difference (p = 0.026). Pain improvements persisted through week 7 (4 weeks after treatment ended), though the study did not assess durability beyond that point.
The device showed selective effects on neuropathic pain symptoms. Participants experienced the greatest improvements in paresthesia and dysesthesia (abnormal skin sensations), paroxysmal pain (sudden shooting pain), and burning pain. However, evoked pain (pain triggered by light touch or pressure) did not improve. No serious device-related adverse events occurred, and participants reported high satisfaction. Blinding integrity held: participants in both groups were similarly uncertain about whether they had received active or sham treatment.
Complementary, not primary. The study was carefully designed to test whether laser therapy adds value to existing treatment. If you have painful DPN and your current medications aren't fully effective, this represents an evidence-based option to discuss with your clinician. It is not a replacement for standard care.
Short-term benefit window. The data support pain relief over 3 weeks of use and durability through week 7. We do not know what happens after that: whether benefits persist, fade, require ongoing maintenance, or plateau. A longer follow-up would clarify realistic expectations.
Not universal. One-third of sham-treated participants also improved, which is typical in pain research and reflects regression to the mean, placebo effects, and natural fluctuation in neuropathic pain. About 27% of active-treated participants did not meet the 30% pain reduction threshold, so individual responses vary.
Specific symptom targeting. If your DPN is primarily characterized by burning, shooting, or pins-and-needles sensations, this device may be more relevant than if your dominant symptom is pain from light touch or pressure.
Mechanism unclear. The study does not explain how red and violet laser light reduce neuropathic pain. Proposed mechanisms in the literature include enhanced mitochondrial ATP production, reduced inflammatory signaling, and modulation of nerve fiber function, but this study provides no direct evidence for any mechanism.
| Attribute | Details |
|---|---|
| Study type | Randomized, double-blind, sham-controlled trial |
| Sample size | 64 participants (33 active, 31 sham) |
| Population | Adults with painful diabetic peripheral neuropathy |
| Sites | 4 independent U.S. clinical centers |
| Intervention | Dual-wavelength laser device (640 nm red + 405 nm violet), 5 min per foot, twice daily |
| Duration | 3 weeks active treatment; follow-up through week 7 |
| Primary outcome | Proportion achieving 30% or greater VAS pain reduction at week 3 |
| Primary result | 72.7% active vs 32.3% sham (p = 0.0024) |
| Secondary outcomes | VAS score change, neuropathic pain inventory, satisfaction, durability, adverse events |
| Concomitant care | Participants maintained stable analgesic and neuropathic pain medications |
| Serious adverse events | None reported |
| Journal | Pain Research & Management |
Levin DF, et al. Dual-Wavelength Laser Therapy for Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, and Sham-Controlled Trial. *Pain Research & Management*. PubMed. https://pubmed.ncbi.nlm.nih.gov/42860829/
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.
| 42860829 |